AAV Vector Delivery of Antibody Genes to Brain Endothelial Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering therapeutic antibodies to the central nervous system (CNS) face significant challenges due to the blood-brain barrier (BBB), with only 0.1%-0.3% of injected antibodies reaching the brain, and existing strategies often result in insufficient therapeutic concentrations and immunogenicity issues.
Innovation Solution
Delivering genes coding for antibodies or antibody fragments using viral vectors, such as AAV, to brain endothelial cells, which express and secrete high-quality antibodies into the CNS, bypassing the need for antibodies to cross the BBB, and utilizing improved expression cassettes with alternative chain positions and secretion peptides to enhance yield and quality.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If therapeutic antibodies are administered systemically to treat CNS diseases, then the antibody can reach the bloodstream, but only 0.1%-0.3% reaches the brain due to the blood-brain barrier
Solution Approach 1:
The patent uses an adeno-associated virus (AAV) vector as an intermediary to deliver antibody-encoding genes to brain endothelial cells. The virus acts as a mediator that can cross the blood-brain barrier and transfer genetic material into the target cells, which then produce and secrete antibodies directly into the CNS, bypassing the barrier's obstruction to antibody delivery
Solution Approach 2:
The patent replaces the mechanical/passive process of antibody diffusion across the blood-brain barrier with a biological production system. Instead of attempting to force antibodies through the barrier, the system uses viral transduction to introduce genes into brain endothelial cells, which then actively synthesize and secrete antibodies directly into the CNS, substituting passive diffusion with active localized production
2Quantity of substance
If high doses of antibodies are injected to overcome the blood-brain barrier limitation, then more antibody may reach the brain, but it causes increased immunogenicity and side effects
Solution Approach 1:
The patent implements local quality by enabling brain endothelial cells to produce and secrete antibodies directly into the central nervous system. This localized production ensures high antibody concentrations are achieved specifically in the CNS where needed, rather than requiring high systemic doses that would cause immunogenicity and side effects throughout the body
Solution Approach 2:
The patent employs self-service by using the host brain endothelial cells as factories to produce the therapeutic antibodies. Once the AAV delivers the antibody-encoding genes, the endothelial cells autonomously synthesize and secrete the antibodies into the CNS, eliminating the need for continuous external administration and avoiding the immunogenicity associated with repeated high-dose injections
3Quantity of substance
If viral vectors are used to deliver antibody genes to brain endothelial cells, then antibody production in the CNS is achieved, but the complexity of the delivery system increases
Solution Approach 1:
The patent applies universality by using brain endothelial cells to perform multiple functions: they serve as the target for viral transduction, as the site of antibody production, and as the secretion pathway into the CNS. This multi-functionality simplifies the overall system compared to using separate delivery and production mechanisms, as the endothelial cells naturally positioned at the blood-brain barrier interface can handle the entire process
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly increases antibody concentrations in the CNS, achieving therapeutic levels and reducing immunogenicity by local production within the brain parenchyma, thereby effectively treating CNS-related disorders.
Implementation Method 1
transduction of brain endothelial cells in vitro by vectors such as adeno-associated virus (AAV) vectors leads to secretion of high quality antibodies
Implementation Method 2
transduction of brain endothelial cells in vitro by vectors such as adeno-associated virus (AAV) vectors leads to secretion of high quality antibodies in large quantity into the basolateral space
Data Source
AI summary
A vector comprises a polynucleotide encoding an antibody or antibody fragment for use in a method of treatment of a disease or disorder of the central nervous system (CNS) in a subject, wherein the vector transduces or transfects cells of the blood brain barrier (BBB) and the transduced or transfected BBB cells express the antibody or antibody fragment resulting in delivery of the antibody or antibody fragment into the CNS, preferably into the brain parenchyma. Expression cassettes useful in such vectors may comprise from 5′ to 3′: at least one promoter operably linked to a first gene encoding a light chain of an antibody or antibody fragment and to a second gene encoding a heavy chain of the antibody or antibody fragment and further comprise an IRES after the first gene encoding the light chain of the antibody or antibody fragment and before the second gene encoding the heavy chain of the antibody or antibody fragment or a first promoter operably linked to a first gene encoding a light chain of an antibody or antibody fragment and a second promoter operably linked to a second gene encoding a heavy chain of the antibody or antibody fragment. The antibodies and antibody fragments thus produced may be of higher quality, displaying lower levels of aggregation and unwanted immunogenicity.